- Home
- MIRM vs LTH Comparison
MIRM vs LTH Comparison
Compare MIRM & LTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- LTH
- Stock Information
- Founded
- MIRM 2018
- LTH 1992
- Country
- MIRM United States
- LTH United States
- Employees
- MIRM N/A
- LTH N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- LTH Hotels/Resorts
- Sector
- MIRM Health Care
- LTH Consumer Discretionary
- Exchange
- MIRM Nasdaq
- LTH Nasdaq
- Market Cap
- MIRM 2.5B
- LTH 6.3B
- IPO Year
- MIRM 2019
- LTH 2021
- Fundamental
- Price
- MIRM $52.66
- LTH $29.60
- Analyst Decision
- MIRM Strong Buy
- LTH Buy
- Analyst Count
- MIRM 9
- LTH 13
- Target Price
- MIRM $66.22
- LTH $34.42
- AVG Volume (30 Days)
- MIRM 456.2K
- LTH 3.4M
- Earning Date
- MIRM 08-06-2025
- LTH 08-05-2025
- Dividend Yield
- MIRM N/A
- LTH N/A
- EPS Growth
- MIRM N/A
- LTH 174.52
- EPS
- MIRM N/A
- LTH 0.96
- Revenue
- MIRM $379,251,000.00
- LTH $2,730,319,000.00
- Revenue This Year
- MIRM $35.83
- LTH $14.61
- Revenue Next Year
- MIRM $16.83
- LTH $11.38
- P/E Ratio
- MIRM N/A
- LTH $30.90
- Revenue Growth
- MIRM 69.31
- LTH 18.58
- 52 Week Low
- MIRM $36.17
- LTH $18.76
- 52 Week High
- MIRM $54.23
- LTH $34.99
- Technical
- Relative Strength Index (RSI)
- MIRM 64.66
- LTH 54.44
- Support Level
- MIRM $49.22
- LTH $28.81
- Resistance Level
- MIRM $53.86
- LTH $29.75
- Average True Range (ATR)
- MIRM 1.57
- LTH 0.87
- MACD
- MIRM 0.08
- LTH 0.07
- Stochastic Oscillator
- MIRM 79.63
- LTH 67.53
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About LTH Life Time Group Holdings Inc.
Life Time Group Holdings Inc is a lifestyle and leisure brand offering health, fitness, and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.